These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25135384)

  • 21. Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada.
    Goeree R; Goeree J
    J Med Econ; 2016; 19(3):277-91. PubMed ID: 26535790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined oral prolonged-release oxycodone and naloxone in chronic pain management.
    Mercadante S; Giarratano A
    Expert Opin Investig Drugs; 2013 Jan; 22(1):161-6. PubMed ID: 23215628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged-release oxycodone/naloxone in opioid-naïve patients - subgroup analysis of a prospective observational study.
    Hesselbarth S; Hermanns K; Oepen P
    Expert Opin Pharmacother; 2015 Mar; 16(4):457-64. PubMed ID: 25612469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developments in managing severe chronic pain: role of oxycodone-naloxone extended release.
    Fanelli G; Fanelli A
    Drug Des Devel Ther; 2015; 9():3811-6. PubMed ID: 26229442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison between the administration of oral prolonged-release oxycodone-naloxone and transdermal fentanyl in patients with moderate-to-severe cancer pain: a propensity score analysis.
    Roberto A; Greco MT; Legramandi L; Galli F; Galli M; Corli O
    J Pain Res; 2017; 10():2123-2133. PubMed ID: 28919810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
    Smith K; Hopp M; Mundin G; Leyendecker P; Bailey P; Grothe B; Uhl R; Reimer K
    Clin Ther; 2008 Nov; 30(11):2051-68. PubMed ID: 19108793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids.
    Ueberall MA; Mueller-Schwefe GH
    J Pain Res; 2015; 8():459-75. PubMed ID: 26300655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients.
    Guerriero F; Sgarlata C; Marcassa C; Ricevuti G; Rollone M
    Clin Interv Aging; 2015; 10():1-11. PubMed ID: 25565782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-analgesic effects of opioids: management of opioid-induced constipation by peripheral opioid receptor antagonists: prevention or withdrawal?
    Holzer P
    Curr Pharm Des; 2012; 18(37):6010-20. PubMed ID: 22747544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxycodone/naloxone in the management of patients with pain and opioid-induced bowel dysfunction.
    Leppert W
    Curr Drug Targets; 2014 Jan; 15(1):124-35. PubMed ID: 24020972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of prolonged-released oxycodone/naloxone in postoperative pain management after total knee replacement: a nonrandomized prospective trial.
    Oppermann J; Bredow J; Spies CK; Lemken J; Unglaub F; Boese CK; Dargel J; Eysel P; Zöllner J
    J Clin Anesth; 2016 Sep; 33():491-7. PubMed ID: 27555214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review.
    Leppert W
    Adv Ther; 2010 Oct; 27(10):714-30. PubMed ID: 20799006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical and economical evaluation of new analgesics for the management of chronic pain].
    Coluzzi F; Ruggeri M
    Recenti Prog Med; 2014 Nov; 105(11):415-9. PubMed ID: 25424235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial.
    Lee KH; Kim TW; Kang JH; Kim JS; Ahn JS; Kim SY; Yun HJ; Eum YJ; Koh SA; Kim MK; Hong YS; Kim JE; Lee GW
    Chin J Cancer; 2017 Sep; 36(1):74. PubMed ID: 28893309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer.
    Clemens KE; Quednau I; Klaschik E
    Int J Clin Pract; 2011 Apr; 65(4):472-8. PubMed ID: 21401835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged-release oxycodone/naloxone in postoperative pain management: from a randomized clinical trial to usual clinical practice.
    Kuusniemi K; Zöllner J; Sjövall S; Huhtala J; Karjalainen P; Kokki M; Lemken J; Oppermann J; Kokki H
    J Int Med Res; 2012; 40(5):1775-93. PubMed ID: 23206459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Opioid-induced constipation in chronic pain: Experience with 180 patients.
    Velázquez Rivera I; Velázquez Clavarana L; García Velasco P; Melero Ramos C
    J Opioid Manag; 2019; 15(1):69-76. PubMed ID: 30855724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.
    Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
    Eur J Pain; 2017 Oct; 21(9):1528-1537. PubMed ID: 28641363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Burden of Opioid-Induced Constipation: Discordance Between Patient and Health Care Provider Reports.
    LoCasale RJ; Datto C; Wilson H; Yeomans K; Coyne KS
    J Manag Care Spec Pharm; 2016 Mar; 22(3):236-45. PubMed ID: 27003553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain.
    Ahmedzai SH; Nauck F; Bar-Sela G; Bosse B; Leyendecker P; Hopp M
    Palliat Med; 2012 Jan; 26(1):50-60. PubMed ID: 21937568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.